Joy has over 15 years professional experience in healthcare and life sciences across research and development, corporate development and strategy, and public and private investing.
Joy joined Abingworth in December 2022, where he works with the team in Boston, London and Menlo Park offices to identify new investment opportunities and support existing investments through to exit. Joy joined the Abingworth team after serving as Portfolio Manager and Managing Director at Eventide Asset Management, where he led their healthcare and life sciences investment practice and served as board director or board observer for several portfolio companies.
Prior to Eventide, Joy was a Vice President at Bain Capital Life Sciences where he focused on growth equity investments across healthcare and life sciences. Joy joined Bain Capital after helping to establish two new therapeutic areas including Ophthalmology and Rare Neuromuscular Diseases at Biogen, in the Corporate Development & Strategy group.
Joy started his career in the biopharma industry as an Investigator at the Novartis Institutes of BioMedical Research (NIBR), the R&D division of Novartis Pharma. While at Novartis, Joy’s team developed several first-in-class monoclonal antibodies that entered human clinical trials.
Joy completed his post-doctoral research in Neuroscience at the Brigham and Women’s Hospital/Harvard Medical School and Boston University School of Medicine. He has a PhD in Biomolecular Structure and Design from the University of Washington, and a BS in Biochemistry at the University of Texas.
